198 related articles for article (PubMed ID: 32654508)
1. Analytical validation of an error-corrected ultra-sensitive ctDNA next-generation sequencing assay.
Fettke H; Steen JA; Kwan EM; Bukczynska P; Keerthikumar S; Goode D; Docanto M; Ng N; Martelotto L; Hauser C; Southey MC; Azad AA; Nguyen-Dumont T
Biotechniques; 2020 Aug; 69(2):133-140. PubMed ID: 32654508
[TBL] [Abstract][Full Text] [Related]
2. Analytical performance evaluation of a commercial next generation sequencing liquid biopsy platform using plasma ctDNA, reference standards, and synthetic serial dilution samples derived from normal plasma.
Verma S; Moore MW; Ringler R; Ghosal A; Horvath K; Naef T; Anvari S; Cotter PD; Gunn S
BMC Cancer; 2020 Oct; 20(1):945. PubMed ID: 33004033
[TBL] [Abstract][Full Text] [Related]
3. Analytical and clinical validation of a novel amplicon-based NGS assay for the evaluation of circulating tumor DNA in metastatic colorectal cancer patients.
Wang B; Wu S; Huang F; Shen M; Jiang H; Yu Y; Yu Q; Yang Y; Zhao Y; Zhou Y; Pan B; Liu T; Guo W
Clin Chem Lab Med; 2019 Sep; 57(10):1501-1510. PubMed ID: 31339850
[TBL] [Abstract][Full Text] [Related]
4. Error-Corrected Deep Targeted Sequencing of Circulating Cell-Free DNA from Colorectal Cancer Patients for Sensitive Detection of Circulating Tumor DNA.
Frydendahl A; Rasmussen MH; Jensen SØ; Henriksen TV; Demuth C; Diekema M; Ditzel HJ; Wen SWC; Pedersen JS; Dyrskjøt L; Andersen CL
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673836
[TBL] [Abstract][Full Text] [Related]
5. Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer.
Vandekerkhove G; Struss WJ; Annala M; Kallio HML; Khalaf D; Warner EW; Herberts C; Ritch E; Beja K; Loktionova Y; Hurtado-Coll A; Fazli L; So A; Black PC; Nykter M; Tammela T; Chi KN; Gleave ME; Wyatt AW
Eur Urol; 2019 Apr; 75(4):667-675. PubMed ID: 30638634
[TBL] [Abstract][Full Text] [Related]
6. Ultrasensitive Detection of Circulating Tumor DNA in Lymphoma via Targeted Hybridization Capture and Deep Sequencing of Barcoded Libraries.
Alcaide M; Rushton C; Morin RD
Methods Mol Biol; 2019; 1956():383-435. PubMed ID: 30779047
[TBL] [Abstract][Full Text] [Related]
7. Generic Protocols for the Analytical Validation of Next-Generation Sequencing-Based ctDNA Assays: A Joint Consensus Recommendation of the BloodPAC's Analytical Variables Working Group.
Godsey JH; Silvestro A; Barrett JC; Bramlett K; Chudova D; Deras I; Dickey J; Hicks J; Johann DJ; Leary R; Lee JSH; McMullen J; McShane L; Nakamura K; Richardson AO; Ryder M; Simmons J; Tanzella K; Yee L; Leiman LC
Clin Chem; 2020 Sep; 66(9):1156-1166. PubMed ID: 32870995
[TBL] [Abstract][Full Text] [Related]
8. Strategies for improving detection of circulating tumor DNA using next generation sequencing.
Tébar-Martínez R; Martín-Arana J; Gimeno-Valiente F; Tarazona N; Rentero-Garrido P; Cervantes A
Cancer Treat Rev; 2023 Sep; 119():102595. PubMed ID: 37390697
[TBL] [Abstract][Full Text] [Related]
9. A high-throughput protocol for isolating cell-free circulating tumor DNA from peripheral blood.
Pandoh PK; Corbett RD; McDonald H; Alcaide M; Kirk H; Trinh E; Haile S; MacLeod T; Smailus D; Bilobram S; Mungall AJ; Ma Y; Moore RA; Coope R; Zhao Y; Jones SJ; Holt RA; Karsan A; Morin RD; Marra MA
Biotechniques; 2019 Feb; 66(2):85-92. PubMed ID: 30744412
[TBL] [Abstract][Full Text] [Related]
10. Heterogeneous mutation pattern in tumor tissue and circulating tumor DNA warrants parallel NGS panel testing.
Guo Q; Wang J; Xiao J; Wang L; Hu X; Yu W; Song G; Lou J; Chen J
Mol Cancer; 2018 Aug; 17(1):131. PubMed ID: 30153823
[TBL] [Abstract][Full Text] [Related]
11. Design of a Targeted Sequencing Assay to Detect Rare Mutations in Circulating Tumor DNA.
Chen J; Chen J; He F; Huang Y; Lu S; Fan H; Wang M; Xu R
Genet Test Mol Biomarkers; 2019 Apr; 23(4):264-269. PubMed ID: 30986100
[TBL] [Abstract][Full Text] [Related]
12. Liquid Biopsy by Next-Generation Sequencing: a Multimodality Test for Management of Cancer.
El Achi H; Khoury JD; Loghavi S
Curr Hematol Malig Rep; 2019 Oct; 14(5):358-367. PubMed ID: 31346903
[TBL] [Abstract][Full Text] [Related]
13. Multiplex detection of ctDNA mutations in plasma of colorectal cancer patients by PCR/SERS assay.
Lyu N; Rajendran VK; Diefenbach RJ; Charles K; Clarke SJ; Engel A; ; Rizos H; Molloy MP; Wang Y
Nanotheranostics; 2020; 4(4):224-232. PubMed ID: 32923312
[TBL] [Abstract][Full Text] [Related]
14. Clinical determinants for successful circulating tumor DNA analysis in prostate cancer.
Schweizer MT; Gulati R; Beightol M; Konnick EQ; Cheng HH; Klemfuss N; De Sarkar N; Yu EY; Montgomery RB; Nelson PS; Pritchard CC
Prostate; 2019 May; 79(7):701-708. PubMed ID: 30865311
[TBL] [Abstract][Full Text] [Related]
15. Molecular tumor analysis and liquid biopsy: a feasibility investigation analyzing circulating tumor DNA in patients with central nervous system lymphomas.
Hickmann AK; Frick M; Hadaschik D; Battke F; Bittl M; Ganslandt O; Biskup S; Döcker D
BMC Cancer; 2019 Mar; 19(1):192. PubMed ID: 30823914
[TBL] [Abstract][Full Text] [Related]
16. Personalized Cancer Monitoring Assay for the Detection of ctDNA in Patients with Solid Tumors.
Zhao J; Reuther J; Scozzaro K; Hawley M; Metzger E; Emery M; Chen I; Barbosa M; Johnson L; O'Connor A; Washburn M; Hartje L; Reckase E; Johnson V; Zhang Y; Westheimer E; O'Callaghan W; Malani N; Chesh A; Moreau M; Daber R
Mol Diagn Ther; 2023 Nov; 27(6):753-768. PubMed ID: 37632661
[TBL] [Abstract][Full Text] [Related]
17. Recent Advances in Liquid Biopsy in Precision Oncology Research.
Sato Y; Matoba R; Kato K
Biol Pharm Bull; 2019; 42(3):337-342. PubMed ID: 30828064
[TBL] [Abstract][Full Text] [Related]
18. Structural variation and fusion detection using targeted sequencing data from circulating cell free DNA.
Gawroński AR; Lin YY; McConeghy B; LeBihan S; Asghari H; Koçkan C; Orabi B; Adra N; Pili R; Collins CC; Sahinalp SC; Hach F
Nucleic Acids Res; 2019 Apr; 47(7):e38. PubMed ID: 30759232
[TBL] [Abstract][Full Text] [Related]
19. [Detection of circulating tumor DNA in epidermal growth factor receptor-TKI relapsed non-small cell lung cancer patients using next-generation sequencing and an analysis of the resistant mechanisms].
Li Y; Zhang FS; Guo L; Ying JM
Zhonghua Bing Li Xue Za Zhi; 2018 Dec; 47(12):904-909. PubMed ID: 30522169
[No Abstract] [Full Text] [Related]
20. The relevance of tumor mutation profiling in interpretation of NGS data from cell-free DNA in non-small cell lung cancer patients.
Ottestad AL; Wahl SGF; Grønberg BH; Skorpen F; Dai HY
Exp Mol Pathol; 2020 Feb; 112():104347. PubMed ID: 31759951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
